Glenn Pierce and Steve Pipe discuss the latest updates on Gene Therapy for hemophilia | July 2021
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician […]
Proceedings of the WFH’s Eleventh Global Forum on Research and Treatment Products for Bleeding Disorders
A summary of discussions held at the Eleventh WFH Global Forum on Research and Treatment Products for Bleeding Disorders which brings together patient groups, healthcare providers, researchers, regulators, industry representatives, and not-for-profit fractionators.
Proceedings of the WFH’s Tenth Global Forum on Research and Treatment Products for Bleeding Disorders
A summary of discussions held at the Tenth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which brings together patient groups, healthcare providers, researchers, regulators, industry representatives, and not-for-profit fractionators.
Proceedings of the WFH’s Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders
A summary of discussions held at the Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which brings together patient groups, healthcare providers, researchers, regulators, industry representatives, and not-for-profit fractionators.
Proceedings of the WFH’s Seventh Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia Treatment Products, which brings together patient groups, healthcare providers, regulators, industry representatives, and not-for-profit fractionators.
Proceedings of the WFH’s Sixth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia Treatment Products, which brings together patient groups, healthcare providers, regulators, industry representatives, and not-for-profit fractionators.
Contract Fractionation
A comprehensive guide to creating and maintaining a successful contract fractionation program, from contract agreements to the fractionation process, the roles of national health officials and foreign fractionators, and other technical, regulatory, and economical considerations.
Proceedings of the WFH’s Fifth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia Treatment Products, which brings together patient groups, healthcare providers, regulators, industry representatives, and not-for-profit fractionators.
Proceedings of the WFH’s Fourth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia Treatment Products, which brings together patient groups, healthcare providers, regulators, industry representatives, and not-for-profit fractionators.
The Safety of Plasma-Derived versus Recombinant Concentrates
In this monograph, the author offers his perspective on the risk of infection from recombinant and plasma-derived products.
Transmissible Agents and the Safety of Coagulation Factor Concentrates
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Russian A multifaceted approach that includes safety measures at every stage of production is needed to minimize the risk of viral transmission by coagulation factor replacement products.
Small Pool Heat-Treated Intermediate Purity Factor VIII Concentrate
Small pool heat-treated intermediate purity concentrate may be the most suitable and cost-effective solution for some countries attempting sufficiency and who cannot afford high-purity products.